News | December 03, 2013

Targeted Brain Cooling May Improve Outcomes, Survival for Cardiac Arrest Patients

rhinochill, RhinoChill, benechill, BeneChill

RhinoChill IntraNasal Cooling System

December 3, 2013 – With the benefits of conventional strategies for therapeutic hypothermia following cardiac arrest being called in to question following the publication of two new studies, brain protection specialist BeneChill has restated its conviction that early, targeted brain cooling is the key to improved neurological outcome and survival for the estimated 700,000 people in Europe who annually suffer cardiac arrest.

The TTM (Targeted Temperature Management) trial, presented at the American Heart Association and published simultaneously in the New England Journal of Medicine [1], demonstrated that preventing hyperthermia by maintaining the body temperature of cardiac arrest patients at only slightly lower than normal temperature (36°C) when cooled in hospital was as effective as cooling them to 33°C with regard to survival and improving neurological outcomes.

A second study, also presented at the American Heart Association and published simultaneously in the Journal of the American Medical Association [2], suggested that using 2 liters of 4.0oC Normal Saline to initiate the body cooling process in cardiac arrest patients before their arrival at the hospital did not improve survival or neurological outcomes compared with those patients in whom the cooling process was only initiated once they reached the hospital.

“The results from both these studies are certainly important, but they do not mean that we should abandon the whole concept of out-of-hospital cooling in cardiac arrest patients,” commented Professor Maaret Castren of the Karolinska Institute, Stockholm, Sweden and Chair of the European Resuscitation Council. “The TTM study managed temperature only in hospital with no pre-hospital cooling used, while the Saline Study describes the lack of benefit, as well as the harmful effects caused, when cold saline is used to start the cooling process after the return of spontaneous circulation. The PRINCE study, of which I was lead investigator, suggested that intra-arrest intranasal evaporative brain cooling can improve brain intact survival. Confirmation of this finding is currently being assessed in a larger, enrolling clinical study, PRINCESS, which is powered for outcome benefit.”

RhinoChill is a portable, non-invasive and easy-to-use system for protecting the brain both during and following cardiac arrest. It rapidly and effectively cools the brain through the evaporation of a coolant liquid in the nasopharynx. A randomized, multi-center, European clinical study [3] has demonstrated safety and a clear trend towards efficacy for brain intact survival following Cardiac Arrest. A sub-analysis demonstrated a statistically significant brain intact survival benefit for
the RhinoChill-treated patients receiving CPR within 10 minutes of the arrest, compared with patients who did not receive early RhinoChill cooling (all patients received standard ICU in-hospital cooling).

Clinical investigators are currently enrolling patients into a larger follow-up trial, PRINCESS. This is another randomized, multi-center European clinical study for the very early, intra-arrest, pre-hospital use of RhinoChill in Cardiac Arrest patients. Following an interim analysis by an independent group of European physicians on the first 210 patients, the investigators of PRINCESS have been encouraged to continue patient enrollment.

“Despite the findings of these recent studies, we remain convinced that brain protection, through early, targeted brain cooling, is the key to improved neurological outcome and survival for cardiac arrest patients,” concluded BeneChill CEO Fred Colen. “This is why we have developed the RhinoChill Intra-Nasal Cooling System, which has the ability to rapidly cool the brain of a sudden cardiac arrest victim.”

For more information: www.rhinochill.com

References
1.      Nielsen N, Wetterslev J, Cronberg T, et al. Targeted temperature management at 33°C versus 36°C after cardiac arrest. N Engl J Med. 2013
[doi:10.1056/NEJMoa1310519]
2.      Kim F, Nichol G, Maynard C, et al. Effect of prehospital induction of mild hypothermia on survival and neurological status among adults with cardiac arrest: A randomized clinical trial. JAMA. 2013
[doi:10.1001/jama.2013.282173]
3.      Castren M, Nordberg P, Svensson L et al. Intra-Arrest Transnasal Evaporative Cooling: A Randomized, Prehospital Multicenter Study.
Circulation 2010; 122: 729-736.

Related Content

DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Overlay Init